Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer
Treatment with high corticosteroid peak dose for irAEs is associated with impaired survival in patients with stage IV NSCLC receiving ICI. Treatment of severe irAEs often requires high doses of corticosteroids. However, clinicians should weigh the unfavorable effects of high peak doses against the need for rapid irAE management.
Authors
- L.E.L. Hendriks
- KPM Suijkerbuijk
- W.S.M.E. Theelen
- E.J. van Dijk
- K. Chatzidionysiou
- Y. Suzuki
- M. Verhaert
- J.S. Garcia Morillo
- L.B.M. Hijmering-Kappelle
- G.J.M. Herder
- E.M.W. van de Garde
- E.C. van der Hout
- M.V. Verschueren
- A.T.J. Maria
- F. Bensch
- R.J. Verheijden
- A.M. Sadowksa
- M.M. Smeenk
- A. Takeji
- M. Lidar
- S. Aspeslagh
- A. Llobell
- B.J.M. Peters
- D.F.L. Liew
Institutions
- University Medical Center Groningen (NL)
- Vrije Universiteit Brussel (BE)
- University of Groningen (NL)
- Utrecht University (NL)
- Sheba Medical Center (IL)
- Maastricht University Medical Centre (NL)
- Karolinska Institutet (SE)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Maastricht University (NL)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Fukui Red Cross Hospital (JP)
- St. Antonius Ziekenhuis (NL)
- Kanazawa University Hospital (JP)
- Pharmo Institute (NL)
- Karolinska Development (Sweden) (SE)
- Universitair Ziekenhuis Brussel (BE)
- Institute of Research and Innovation Parc Tauli (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Melbourne Health (AU)
- Meander Medisch Centrum (NL)
- Austin Health (AU)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1016/j.esmoop.2025.106052
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00